Please use this identifier to cite or link to this item:
|Title:||An emerging role of PARK2 in cancer||Authors:||Xu, L.
|Issue Date:||Jan-2014||Citation:||Xu, L., Lin, D.-C., Yin, D., Koeffler, H.P. (2014-01). An emerging role of PARK2 in cancer. Journal of Molecular Medicine 92 (1) : 31-42. ScholarBank@NUS Repository. https://doi.org/10.1007/s00109-013-1107-0||Abstract:||PARK2 (PARKIN) is an E3 ubiquitin ligase involved in multiple signaling pathways and cellular processes. Activity of PARK2 is tightly regulated through inter- and intra-molecular interactions. Dysfunction of PARK2 is associated with the progression of parkinsonism. Notably, frequent PARK2 inactivation has been identified in various human cancers. Park2-deficient mice are more susceptible to tumorigenesis, indicating its crucial role as a tumor suppressor. However, biological studies also show that PARK2 possesses both pro-survival and growth suppressive functions. Here, we summarize the genetic lesions of PARK2 in human cancers and discuss the current knowledge of PARK2 in cancer progression. We further highlight future efforts for the study of PARK2 in cancer. © 2013 Springer-Verlag Berlin Heidelberg.||Source Title:||Journal of Molecular Medicine||URI:||http://scholarbank.nus.edu.sg/handle/10635/125843||ISSN:||09462716||DOI:||10.1007/s00109-013-1107-0|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.